Next-generation PERG devices and methods

下一代PERG设备和方法

• 批准号: 8779609
• 负责人: Jonathon Anthony Toft-Nielsen
• 金额: $ 15.5万
• 依托单位: JORVEC CORPORATION
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8779609
• 关键词: Accounting; Adoption; Advanced Development; Amplifiers; Animal Model; Animals; Biomedical Engineering; Blindness; Cell Death; Cell physiology; Cessation of life; Clinical; Communities; Computer software; Coupled; Data Analyses; Dependency; Detection; Development; Devices; Diagnostic; Dimensions; Disease; Early Diagnosis; Electroretinography; Exhibits; Experimental Models; Eye; Functional disorder; Glaucoma; Goals; Goggles; Head; Health; Human; Influentials; Laboratory mice; Lead; Left; Light; Measurement; Measures; Methods; Monitor; Mus; Noise; Patients; Pattern; Performance; Pharmacologic Substance; Phase; Physiologic Intraocular Pressure; Positioning Attribute; Posture; Public Health; Pupil; Research; Retinal Degeneration; Retinal Diseases; Retinal Ganglion Cells; Rodent; Scientist; Signal Transduction; Staging; Stimulus; System; Techniques; Technology; Testing; Therapeutic; Time; Twin Multiple Birth; Uncertainty; Vision; Vision research; Work; animal model development; base; clinical application; cost; design; digital; functional loss; human subject; improved; in vivo; innovation; laptop; mouse model; next generation; novel; optic nerve disorder; prevent; prototype; public health relevance; response; screening; tool; user-friendly

DESCRIPTION (provided by applicant): Glaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cells (RGC) degeneration, ultimately manifesting in a functional loss of vision if left untreated. There exist a number of therapeutic approaches to treat these conditions, but there are currently no clinical methods to detect the onset of RGC dysfunction. The Pattern Electroretinogram (PERG) is the only established tool to monitor RGC health in vivo in humans and experimental models of optic nerve diseases. The monitoring of PERG responses can potentially provide earlier detection of degenerative retinal disorders such as glaucoma, allowing for treatment paradigms to be initiated before irreversible functional vision loss has occurred. A critical barrier to the widespread adoption of PERG for research and clinical use is the lack of availability of an easy-to-use, turnkey device for recording and data analysis. The goal of the proposed project is to produce commercially available devices for use in both vision research and clinical applications, which are more compact, faster, cheaper and more user-friendly. During Phase I, the following specific aims will pursued: 1) Development of a hardware platform containing a digital signal processor and the necessary amplifiers to interface with the next-generation PERG stimulators. 2) Development of a lightweight LED-based PERG stimulator for animal studies. 3) Development of a lightweight AMOLED-based goggle PERG stimulator for humans. 4) Development of advanced stimulation sequences which will reduce spurious cross talk components. The performance of the prototype devices will be evaluated and optimized. Successful completion of our research will provide allow large community of clinicians and scientists to more easily take advantage of the PERG technique.

描述（由申请人提供）：青光眼是导致视网膜神经节细胞（RGC）变性的多种视神经疾病之一，如果未经治疗，则最终表现为视力丧失。 存在许多治疗这些疾病的治疗方法，但是目前尚无临床方法检测RGC功能障碍的发作。 模式电视图（PERG）是唯一在人体中监测体内RGC健康和视神经疾病实验模型的既定工具。 对PERG反应的监测可以潜在地提供早期检测退行性视网膜疾病（例如青光眼），从而在发生不可逆的功能视觉丧失之前可以启动治疗范例。 PERG广泛采用用于研究和临床使用的关键障碍是缺乏易于使用的易于使用的交钥匙设备进行记录和数据分析。 拟议项目的目标是生产可在视觉研究和临床应用中使用的商业可用设备，这些设备更紧凑，更快，更便宜且用户友好。 在第一阶段，将实现以下特定目标：1）开发包含数字信号处理器的硬件平台以及与下一代PERG刺激器接口的必要放大器。 2）开发用于动物研究的基于LED的轻质perg刺激剂。 3）开发针对人类的基于AMOLED的轻质护目镜刺激剂。 4）开发高级刺激序列，这将减少伪造的交叉谈话组件。 原型设备的性能将得到评估和优化。 成功完成我们的研究将为大型临床医生和科学家社区提供更轻松地利用PERG技术。